Published in Curr Pharm Des on January 01, 2014
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
Ectopic thyroid tissue: anatomical, clinical, and surgical implications of a rare entity. Eur J Endocrinol (2011) 2.37
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J (2004) 2.09
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study. Diabetes Care (2003) 1.79
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol (2013) 1.53
Atorvastatin: safety and tolerability. Expert Opin Drug Saf (2010) 1.47
Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin's lymphoma. Ann Hematol (2004) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
CORONA, statins, and heart failure: who lost the crown? Angiology (2008) 1.38
Is angioedema a class adverse effect of the angiotensin-converting enzyme inhibitors? Ann Allergy Asthma Immunol (2007) 1.38
Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer (2007) 1.34
Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) (2009) 1.29
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol (2006) 1.12
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther (2014) 1.11
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol (2007) 1.09
Pleiotropic effects of statins--clinical evidence. Curr Pharm Des (2009) 1.08
Vitamin D deficiency during pregnancy: confronting the issues. Clin Endocrinol (Oxf) (2013) 1.07
Cold temperature and cardiovascular mortality. Circ J (2013) 1.07
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". Dig Liver Dis (2012) 1.06
Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention. Circ J (2013) 1.06
Metabolic syndrome in clinical practice. Cardiol J (2014) 1.06
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci (2013) 1.01
Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin (2010) 1.01
Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets (2010) 1.01
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother (2008) 1.00
Dyslipidemia as a risk factor for ischemic stroke. Curr Top Med Chem (2009) 0.99
Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol (2006) 0.99
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci (2011) 0.96
Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk? Curr Vasc Pharmacol (2010) 0.95
Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol (2012) 0.95
Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets (2009) 0.95
Statin discontinuation: an underestimated risk? Curr Med Res Opin (2008) 0.95
Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis (2008) 0.94
Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol (2011) 0.94
Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? Curr Opin Cardiol (2010) 0.94
Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment? Arch Med Sci (2011) 0.94
Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients (2013) 0.94
Acupuncture in the treatment of obesity: a narrative review of the literature. Acupunct Med (2012) 0.94
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology (2011) 0.94
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother (2007) 0.93
Hyperuricaemia: more than just a cause of gout? J Cardiovasc Med (Hagerstown) (2013) 0.92
Lipoprotein a: where are we now? Curr Opin Cardiol (2009) 0.92
Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. Nephrol Dial Transplant (2006) 0.92
Carbon dioxide balneotherapy and cardiovascular disease. Int J Biometeorol (2010) 0.92
Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? Expert Opin Pharmacother (2007) 0.91
Are we getting to lipid targets in real life? Arch Med Sci (2010) 0.90
Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother (2010) 0.90
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J (2011) 0.90
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism (2012) 0.89
Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets (2007) 0.89
Rectus sheath hematoma: a simplified emergency surgical approach. Open Cardiovasc Med J (2011) 0.88
The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol (2007) 0.88
Location, number and morphology of parathyroid glands: results from a large anatomical series. Anat Sci Int (2012) 0.87
Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol (2008) 0.87
Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism (2005) 0.87
Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin (2013) 0.87
Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol (2007) 0.86
Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med (2011) 0.86
Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver. Clin Biochem (2011) 0.86
Anti-inflammatory effects of fibrates: an overview. Curr Med Chem (2009) 0.86